Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine
- Study Title
- A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine
- Teva Identifier
- TV48125-CNS-30088
- ClinicalTrials.gov Identifier
- NCT05458011
- Study Status
- Completed
- Trial Condition(s)
- Migraine Headache
- Interventions
- Drug: Fremanezumab | Drug: Placebo
- Study Description
- Primary objectives: The primary Objective is to demonstrate the efficacy of fremanezumab administered as monthly and quarterly subcutaneous (sc) injections to adult Chinese participants with migraine. Secondary objectives: The secondary Objectives are to further demonstrate the efficacy of fremanezumab administered as monthly and quarterly sc injections and to evaluate the safety and tolerability of fremanezumab administered as monthly and quarterly sc injections. The total study duration for participants is planned to be approximately 9 months. The study will consist of a screening visit, a baseline period (4 weeks), a 12-week double-blind treatment period, a 12-week open-label treatment period, and a follow-up period lasting approximately 3 months after the last dose of treatment.
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult
- Age Range
- Adult
- Trial Duration
- August 23, 2022 - June 13, 2024
- Phase
- Phase 3
